# Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis

> **NCT06265272** · — · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Liver Cirrhosis
- Hepatic Cell Carcinoma
- Portal Hypertension

## Interventions

- **DRUG:** Injection of a gadolinium contrast agen
- **DRUG:** Radiotracer Injection
- **DIAGNOSTIC_TEST:** Imaging

## Key facts

- **NCT ID:** NCT06265272
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-10
- **Primary completion:** 2026-12-19
- **Final completion:** 2026-12-19
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06265272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06265272, "Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06265272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*